argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Janeiro 2024 - 3:00AM
Amsterdam, the Netherlands –
argenx (Euronext & Nasdaq: ARGX), a global immunology company
committed to improving the lives of people suffering from severe
autoimmune diseases, today announced that Tim Van Hauwermeiren,
Chief Executive Officer, will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00
a.m. PT.
A live webcast of the presentation may be accessed on the
Investor section of the argenx website at argenx.com/investors. A
replay of the webcast will be available on the argenx website for
approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the
lives of people suffering from severe autoimmune diseases.
Partnering with leading academic researchers through its Immunology
Innovation Program (IIP), argenx aims to translate immunology
breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx developed and is commercializing the first
approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan,
Israel, the EU, the UK, China and Canada. The Company is evaluating
efgartigimod in multiple serious autoimmune diseases and advancing
several earlier stage experimental medicines within its therapeutic
franchises. For more information,
visit www.argenx.com and follow us
on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Ben Petokbpetok@argenx.com
Investors:
Alexandra Roy (US)aroy@argenx.com
Lynn Elton (EU)lelton@argenx.com
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
